BI-4394|1222173-37-6|(MMP13-IN-3)-陌孚医药/Medlife

您当前的位置：

BI-4394 (Synonyms: MMP13-IN-3)

目录号: PL07398 纯度: ≥99%

CAS No. :1222173-37-6

商品编号	规格	价格	会员价
PL07398-5mg	5mg	¥2967.27	请登录
PL07398-10mg	10mg	¥4747.64	请登录
PL07398-50mg	50mg	¥14341.82	请登录
PL07398-100mg	100mg	询价	询价
PL07398-200mg	200mg	询价	询价
PL07398-10mM*1mLinDMSO	10mM*1mLinDMSO	¥3264.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	BI-4394
英文名称	BI-4394
英文别名	compound 15 [PMID: 22017539];MMP13-IN-3;4UF;4-((5-(2-(Ethoxycarbonyl)-1H-indol-5-yl)-1-methyl-1H-pyrazole-3-carboxamido)methyl)benzoic acid;4-[[[5-(2-ethoxycarbonyl-1H-indol-5-yl)-1-methylpyrazole-3-carbonyl]amino]methyl]benzoic acid;4-{[({5-[2-(Ethoxycarbonyl)-1h-Indol-5-Yl]-1-Methyl-1h-Pyrazol-3-Yl}carbonyl)amino]methyl}benzoic Acid;GTPL8636;BDBM50361618;Q27076272;US8785489, 4-{[({5-[2-(ethoxycarbonyl)-1H-indol-5-;BI-4394
Cas No.	1222173-37-6
分子式	C₂₄H₂₂N₄O₅
分子量	446.46
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	BI-4394 (MMP13-IN-3) 是一种有效的，具有口服活性的选择性 MMP-13 抑制剂，IC₅₀ 为 1 nM，比作用于其他 MMP 的选择性高 1000倍多。BI-4394 有潜力用于骨关节炎的研究。
生物活性	BI-4394 (MMP13-IN-3) is a potent, selective, and orally active MMP-13 inhibitor (IC 50 =1 nM) for the potential treatment of osteoarthritis. BI-4394 is >1000 selective over other MMPs.
性状	Solid
IC50 & Target[1][2]	MMP-13 1 nM (IC50) MMP-14 8.3 μM (IC5
体外研究(In Vitro)	BI-4394 (Compound 15) is potent in a full-length MMP-13 collagen degradation assay (11 nM) and is able to inhibit degradation of bovine nasal cartilage with an IC50 of 31 nM. BI-4394 inhibits MMP-2, MMP-9, MMP-10 and MMP-14 with IC50s of 18, 8.9, 16 and 8.3 μM, respectively. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	When dosed orally at 10 mg/kg or i.v. 1 mg/kg, BI-4394 (Compound 15) reaches micromolar plasma levels (AUC=1109±64 nM h/mL), displays modest clearance (CL=34 mL/min/kg), and shows acceptable bioavailability (39%). The V ss is quite low at 0.26 mL/mi/kg rat pharmacokinetic profile. BI-4394 has short terminal elimination half-life (t 1/2 =0.47 h for rat (1 mg/kg, i.v.) and rat (10 mg/kg, orally), respectively). has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Taylor SJ, et al. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J Med Chem. 2011 Dec 8;54(23):8174-87. [2]. Ruminski PG, et al. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis. J Med Chem. 2016 Jan 14;59(1):313-27.

溶解度数据	In Vitro: DMSO : 100 mg/mL (223.98 mM; ultrasonic and warming and heat to 60°C)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation